Table 2.
Comparison between patients who had died or who were alive on ART at the end of the study period
| Variable | All n = 2643 |
Died n = 151a |
Alive on ART n = 2381a |
p^ |
|---|---|---|---|---|
| Age | 37 (31–44) | 40 (33–45) | 37 (31–44) | 0.001 |
| Gender (% male) | 1494 (57%) | 96 (64%) | 1327 (56%) | 0.06 |
| Unemployed | 917 (35%) | 64 (42%) | 814 (34%) | 0.04 |
| Living in a different regionb | 526 (20%) | 43 (30%) | 462 (20%) | 0.005 |
| CD4 + count at registration (cells/mm3) | 169 (59–328) | 45 (23–127) | 183 (65–337) | <0.001 |
| WHO stage at registration | 3 (3–3) | 4 (3–4) | 3 (2–3) | 0.0001 |
| On treatment for tuberculosis | 1124 (43%) | 99 (66%) | 971 (41%) | <0.001 |
| Isoniazid prophylaxis therapyc | 21 (0.8%) | 0 | 20 (0.8%) | 0.26 |
| Co-trimoxazole prophylaxis therapyd | 2125 (81%) | 136 (93%) | 1904 (80%) | <0.001 |
All numbers represent median and interquartile range or absolute number (percentage)
^ Comparison between survivors and those that died using Kruskal–Wallis or Chi squared test
aDoes not include the 111 patients in the cohort lost to follow up
b75 patients did not have an address recorded; 6 patients who died and 69 still alive
cOne patient lost to follow up
d2627 (99%) had data regarding co-trimoxazole prescription